1. Home
  2. STVN vs RGEN Comparison

STVN vs RGEN Comparison

Compare STVN & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STVN
  • RGEN
  • Stock Information
  • Founded
  • STVN 1949
  • RGEN 1981
  • Country
  • STVN Italy
  • RGEN United States
  • Employees
  • STVN N/A
  • RGEN N/A
  • Industry
  • STVN Containers/Packaging
  • RGEN Medical/Dental Instruments
  • Sector
  • STVN Consumer Discretionary
  • RGEN Health Care
  • Exchange
  • STVN Nasdaq
  • RGEN Nasdaq
  • Market Cap
  • STVN 7.4B
  • RGEN 6.5B
  • IPO Year
  • STVN 2021
  • RGEN N/A
  • Fundamental
  • Price
  • STVN $24.66
  • RGEN $152.80
  • Analyst Decision
  • STVN Buy
  • RGEN Buy
  • Analyst Count
  • STVN 4
  • RGEN 11
  • Target Price
  • STVN $25.13
  • RGEN $167.90
  • AVG Volume (30 Days)
  • STVN 355.2K
  • RGEN 952.0K
  • Earning Date
  • STVN 11-04-2025
  • RGEN 10-28-2025
  • Dividend Yield
  • STVN 0.26%
  • RGEN N/A
  • EPS Growth
  • STVN 6.78
  • RGEN N/A
  • EPS
  • STVN 0.57
  • RGEN N/A
  • Revenue
  • STVN $1,344,798,591.00
  • RGEN $673,956,000.00
  • Revenue This Year
  • STVN $8.33
  • RGEN $16.77
  • Revenue Next Year
  • STVN $10.12
  • RGEN $13.79
  • P/E Ratio
  • STVN $41.95
  • RGEN N/A
  • Revenue Growth
  • STVN 5.28
  • RGEN 8.73
  • 52 Week Low
  • STVN $17.12
  • RGEN $102.97
  • 52 Week High
  • STVN $28.00
  • RGEN $182.52
  • Technical
  • Relative Strength Index (RSI)
  • STVN 48.72
  • RGEN 65.63
  • Support Level
  • STVN $23.01
  • RGEN $143.47
  • Resistance Level
  • STVN $24.83
  • RGEN $157.03
  • Average True Range (ATR)
  • STVN 1.29
  • RGEN 6.17
  • MACD
  • STVN -0.15
  • RGEN 0.64
  • Stochastic Oscillator
  • STVN 40.34
  • RGEN 87.20

About STVN Stevanato Group S.p.A.

Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.

About RGEN Repligen Corporation

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

Share on Social Networks: